BioCryst Pharmaceuticals, Inc. (BCRX)

BioCryst Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	105.19	104.71	110.64	304.77	504.39	272.13
Short-Term Investments	189.9	216.14	278.34	119.54	3.21	28.24
Cash & Short-Term Investments	295.09	320.85	388.99	424.31	507.6	300.37
Cash Growth	-12.32%	-17.52%	-8.33%	-16.41%	68.99%	120.49%
Receivables	93.39	79.07	56.95	50.6	29.41	8.65
Inventory	6.87	8.09	28.68	27.53	15.79	7.04
Prepaid Expenses	14.33	13.75	19.54	12.59	9.99	5.53
Restricted Cash	0.29	0.21	1.8	1.47	3.35	2.22
Total Current Assets	409.98	421.97	495.97	516.5	566.14	323.8
Property, Plant & Equipment	19.58	19.79	20.91	15.42	15.19	10.92
Long-Term Investments	20.55	20.32	-	18.08	6.83	-
Other Long-Term Assets	29.95	28.34	0.08	-	-	-
Total Assets	480.05	490.42	516.96	550	588.15	334.72
Accounts Payable	10.05	11.64	20.89	14.36	27.81	18.71
Accrued Expenses	92.64	113.29	102.88	87.57	72.67	55.61
Current Portion of Long-Term Debt	34.31	32.68	23.57	-	-	30
Current Portion of Leases	2.87	2.77	2.65	2.37	1.82	1.18
Current Unearned Revenue	-	-	-	1.22	1.42	0.15
Total Current Liabilities	139.86	160.38	149.99	105.51	103.72	105.65
Long-Term Debt	782.03	795.92	811.27	733.28	585.46	244.45
Long-Term Leases	10.09	10.05	11.24	5.8	5.96	3.87
Total Liabilities	931.97	966.35	972.49	844.6	695.14	353.98
Common Stock	2.09	2.09	2.06	1.88	1.84	1.77
Additional Paid-In Capital	1,315	1,291	1,222	1,158	1,098	1,002
Retained Earnings	-1,770	-1,770	-1,681	-1,455	-1,208	-1,023
Comprehensive Income & Other	1.13	0.92	1.34	0.03	0.18	0
Shareholders' Equity	-451.93	-475.93	-455.53	-294.6	-106.99	-19.26
Total Liabilities & Equity	480.05	490.42	516.96	550	588.15	334.72
Total Debt	829.29	841.42	848.71	741.45	593.24	279.5
Net Cash (Debt)	-534.2	-520.57	-459.73	-317.14	-85.64	20.86
Net Cash Growth	-	-	-	-	-	-59.55%
Net Cash Per Share	-2.58	-2.52	-2.39	-1.71	-0.48	0.12
Filing Date Shares Outstanding	209.25	208.96	206.15	188.45	184.66	177.18
Total Common Shares Outstanding	209.21	208.54	205.77	187.91	184.35	176.88
Working Capital	270.12	261.58	345.98	410.99	462.42	218.15
Book Value Per Share	-2.16	-2.28	-2.21	-1.57	-0.58	-0.11
Tangible Book Value	-451.93	-475.93	-455.53	-294.6	-106.99	-19.26
Tangible Book Value Per Share	-2.16	-2.28	-2.21	-1.57	-0.58	-0.11
Machinery	-	8.41	7.66	6.53	5.84	4.71
Construction In Progress	-	0.1	-	-	-	-
Leasehold Improvements	-	10.36	10.21	10.14	9.83	8.58

Updated May 5, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q